Eureka Therapeutics has started enrolling adults with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, in a Phase 1/2 trial of its investigational ET140203 T-cell therapy. The trial, called ARYA-1 (NCT04502082), seeks to enroll around 50 patients whose tumors contain alpha-fetoprotein (AFP), a protein that is overly produced by some types of malignant cells, including liver cancer cells. Participants are being recruited at the City of Hope Medical Center and the University…
You must be logged in to read/download the full post.
The post Phase 1 Trial of ET140203 T-cell Therapy Starts Enrolling Adults With Advanced Liver Cancer appeared first on BioNewsFeeds.